- Conditions
- Hematologic Malignancies, Solid Tumor
- Interventions
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 47
- States / cities
- Duarte, California • Palo Alto, California • Denver, Colorado + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 2,318
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Radiation
- Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- flow cytometry, immunoenzyme technique, laboratory biomarker analysis
- Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Multiple Myeloma
- Interventions
- Fludarabine, Busulfan, Cyclophosphamide, Total body irradiation (TBI), Peripheral Blood Hematopoietic Cell Transplantation (HCT), Sirolimus (SIR), Mycophenolate mofetil (MMF), Granulocyte-colony stimulating factor (G-CSF)
- Drug · Radiation · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
- Biological · Drug · Other + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Multiple Myeloma
- Interventions
- Oprozomib, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Pomalidomide, Quality-of-Life Assessment, Questionnaire Administration, Selinexor, X-Ray Imaging, Computed Tomography, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- recombinant interferon alfa, recombinant interleukin-12
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Interventions
- arsenic trioxide, ascorbic acid, melphalan, chemosensitization/potentiation, chemotherapy
- Drug · Procedure
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 19
- States / cities
- Glendale, Arizona • Bakersfield, California • Campbell, California + 16 more
- Conditions
- Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma
- Interventions
- Standard developed materials, Genetics Advisor Decision Aid
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Myeloma, Relapse Multiple Myeloma
- Interventions
- Descartes-25
- Drug
- Lead sponsor
- Cartesian Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Shreveport, Louisiana • Bethesda, Maryland
- Conditions
- Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Myeloma in Relapse, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- bevacizumab, lenalidomide, dexamethasone
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Madison, Wisconsin
- Conditions
- Non-Hodgkin's Lymphoma, Leukemia
- Interventions
- Topotecan, Mitozantrone, Etoposide
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Multiple Myeloma, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Interventions
- Administration of hyperbaric oxygen
- Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Refractory Multiple Myeloma
- Interventions
- plerixafor, filgrastim
- Drug · Biological
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 28
- States / cities
- Alabaster, Alabama • Surprise, Arizona • Berkeley, California + 25 more
- Conditions
- Multiple Myeloma
- Interventions
- SGN-CD48A
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- San Francisco, California • New Haven, Connecticut • Tampa, Florida + 3 more
- Conditions
- Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type, Neoplasm, Hemostatic Disorders, Vascular Disorder, Paraproteinemias, Blood Protein Disorders, Hematologic Disease and Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Disease, Gene Therapy
- Interventions
- KLN-1010
- Drug
- Lead sponsor
- Kelonia Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 8
- States / cities
- Duarte, California • Palo Alto, California • San Francisco, California + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Dexamethasone
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more
- Conditions
- Lymphoproliferative Disorder, Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review, Follow-Up, Genetic Counseling, Genetic Testing
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- carboplatin, docetaxel, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Cancer Treatment Centers of America
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Zion, Illinois
- Conditions
- Hematological Malignancies
- Interventions
- Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more
- Conditions
- Lymphoma, B-Cell, Multiple Myeloma
- Interventions
- Live Biotherapeutic Product (LBP), Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois